Alligator Bioscience AB (publ) (STO:ATORX)
Sweden · Delayed Price · Currency is SEK 0.1913
+0.0001 (0.05%)
Jan 21, 2026, 5:29 PM CET
Alligator Bioscience AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 42.25 | 57.77 | 58.11 | 35.7 | 12.94 | 4.35 | Upgrade |
Other Revenue | 3.97 | -0.04 | 1.14 | 0.31 | 0.38 | 1.16 | Upgrade |
| 46.22 | 57.72 | 59.25 | 36 | 13.33 | 5.52 | Upgrade | |
Revenue Growth (YoY) | 66.41% | -2.58% | 64.58% | 170.14% | 141.65% | 26.55% | Upgrade |
Cost of Revenue | 106.63 | 167.21 | 218.79 | 147.73 | 86.98 | 82.32 | Upgrade |
Gross Profit | -60.41 | -109.48 | -159.54 | -111.72 | -73.66 | -76.81 | Upgrade |
Selling, General & Admin | 50.32 | 70.43 | 79.38 | 68.84 | 56.85 | 55.71 | Upgrade |
Other Operating Expenses | 0.47 | -0.12 | -0.02 | -0.03 | -0 | -0 | Upgrade |
Operating Expenses | 94.28 | 119.04 | 89.85 | 80.58 | 68 | 67.23 | Upgrade |
Operating Income | -154.68 | -228.52 | -249.39 | -192.3 | -141.65 | -144.04 | Upgrade |
Interest Expense | -47.27 | -19.69 | -0.48 | -0.65 | -0.23 | -0.31 | Upgrade |
Interest & Investment Income | 0.4 | 1.31 | 1.88 | - | - | 0.19 | Upgrade |
Currency Exchange Gain (Loss) | -2.34 | -1.27 | -0.6 | -0.46 | -0.14 | -0.6 | Upgrade |
Other Non Operating Income (Expenses) | 113.97 | 14.28 | 0 | 0 | - | -0 | Upgrade |
EBT Excluding Unusual Items | -89.92 | -233.89 | -248.59 | -193.41 | -142.03 | -144.75 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | - | - | 1.46 | Upgrade |
Asset Writedown | 12.2 | - | - | - | - | - | Upgrade |
Other Unusual Items | - | - | - | - | -0.96 | - | Upgrade |
Pretax Income | -77.72 | -233.89 | -248.59 | -193.4 | -141.74 | -143.3 | Upgrade |
Net Income | -77.72 | -233.89 | -248.59 | -193.4 | -141.74 | -143.3 | Upgrade |
Net Income to Common | -77.72 | -233.89 | -248.59 | -193.4 | -141.74 | -143.3 | Upgrade |
Shares Outstanding (Basic) | 17 | 1 | 0 | 0 | 0 | 0 | Upgrade |
Shares Outstanding (Diluted) | 17 | 1 | 0 | 0 | 0 | 0 | Upgrade |
Shares Change (YoY) | 2322.13% | 63.72% | 103.32% | 146.00% | 25.61% | - | Upgrade |
EPS (Basic) | -4.63 | -318.53 | -554.27 | -876.77 | -1580.64 | -2007.26 | Upgrade |
EPS (Diluted) | -4.70 | -320.00 | -554.27 | -880.00 | -1580.64 | -2010.00 | Upgrade |
Free Cash Flow | -165.18 | -212.43 | -191.74 | -173.05 | -127.08 | -141.45 | Upgrade |
Free Cash Flow Per Share | -9.84 | -289.30 | -427.53 | -784.49 | -1417.17 | -1981.45 | Upgrade |
Gross Margin | -130.70% | -189.67% | -269.26% | - | - | - | Upgrade |
Operating Margin | -334.68% | -395.90% | -420.90% | -534.16% | -1062.89% | -2611.71% | Upgrade |
Profit Margin | -168.15% | -405.19% | -419.55% | -537.22% | -1063.52% | -2598.30% | Upgrade |
Free Cash Flow Margin | -357.39% | -368.01% | -323.61% | -480.67% | -953.54% | -2564.90% | Upgrade |
EBITDA | -158.97 | -227.58 | -248.24 | -188.89 | -136.7 | -138.51 | Upgrade |
D&A For EBITDA | -4.29 | 0.95 | 1.15 | 3.41 | 4.95 | 5.53 | Upgrade |
EBIT | -154.68 | -228.52 | -249.39 | -192.3 | -141.65 | -144.04 | Upgrade |
Revenue as Reported | 48.07 | 59.71 | 61.9 | 37.14 | 15.13 | 6.67 | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.